Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.

Hamza S GorsiParitosh C KhannaMark TumblinLanipua Yeh-NayreMehrzad MilburnJennifer D ElsterJohn R Crawford

Published in: Pediatric blood & cancer (2018)

Single-agent bevacizumab is efficacious in the management of recurrent or refractory pediatric LGG with radiographic and clinical responses similar to those reported for bevacizumab-based therapies.

Keyphrases

low grade
metastatic colorectal cancer
high grade
replacement therapy